Market Overview
Hypertrophic cardiomyopathies are the result of genetic mutations in one or a few genes; therefore, the disease is caused by gene defects. Several other genes, such as those that encode enzymes that facilitate protein synthesis and insulin secretion, are also believed to be involved in the development of this condition. Inheritance is also a possibility, as are viral diseases and drug toxicity. Some individuals who suffer from this condition may also have other cardiovascular or cerebrovascular diseases or conditions.
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1674
Market Dynamics
Increasing obesity and sedentary lifestyle population are expected to drive growth of the global hypertrophic cardiomyopathy (HCM) therapeutics market during the forecast period. As per the World Health Organization (WHO), in 2016, over 1.9 billion adults aged 18 years and above were overweight, of which around 650 million were obese. As per the same source, in 2016, around 340 million children and adolescents aged 5-19 years were overweight or obese. Obese people are at the most risk of hypertrophic cardiomyopathy that makes heart muscle abnormally thick. Hence, such factors are expected to drive growth of the global hypertrophic cardiomyopathy (HCM) therapeutics market during the forecast period.
However, the high cost of treatment hypertrophic cardiomyopathy is expected to hamper the global hypertrophic cardiomyopathy (HCM) therapeutics market growth over the forecast period.
Impact of COVID-19
The global blood irradiator market witnessed a sharp decline following the outbreak of the COVID-19 pandemic. Many countries implemented stringent regulations on travel and physical distancing, in order to curb the spread of the virus. These regulations further disrupted the global supply chain industry massively, rendering a decrease in demand for blood irradiators. However, the rollout of vaccines and declining cases of COVID-19 is expected to aid in growth of the global blood irradiator market in the near future.
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/1674
Key Takeaways
-
The global hypertrophic cardiomyopathy (HCM) therapeutics market is expected to expand, exhibiting a CAGR of 2.0 % over the forecast period. This is owing to new product development for targeted cardiac disorders such as coronary heart disease, cerebrovascular disease, and more. For instance, in May 2020, AstraZeneca Pharmaceuticals LP Wilmington, DE received the U.S. Food and Drug Administration (FDA) approval for Farxiga tablets for the treatment of heart failure in adults.
-
Among regions, North America is expected to witness significant growth in the global hypertrophic cardiomyopathy (HCM) therapeutics market during the forecast period. This is owing to the presence of robust healthcare infrastructure in the region.
-
Key companies involved in the global hypertrophic cardiomyopathy (HCM) therapeutics market are Sanofi S.A., Merck & Co., Pfizer, Inc., Mylan N. V., MyoKardia, Inc., Teva Pharmaceutical Industries Ltd., and Novartis AG.
𝗖𝗵𝗿𝗶𝘀𝘁𝗺𝗮𝘀 𝗦𝗮𝗹𝗲 𝗜𝘀 𝗟𝗶𝘃𝗲!
𝗕𝘂𝘆 𝗡𝗼𝘄 𝗧𝗼 𝗔𝘃𝗮𝗶𝗹 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝗙𝗿𝗼𝗺 𝟮𝟱-𝟯𝟬% 𝘁𝗶𝗹𝗹 𝟯𝟭-𝗗𝗲𝗰-𝟮𝟬𝟮𝟭
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1674
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Hypertrophic Cardiomyopathy (HCM) Therapeutics Industry Impact
Chapter 2 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics (Volume and Value) by Type
2.3 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 6 East Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 7 Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 8 South Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 9 Southeast Asia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 10 Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 11 Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 12 Oceania Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 13 South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Hypertrophic Cardiomyopathy (HCM) Therapeutics Business
Chapter 15 Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
Continued….
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837